기본 콘텐츠로 건너뛰기

2022.07.28_ginsenoside

Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats. Biol Pharm Bull. 2011;34(8):1319-24.

  • Right after the onset of Middle Cerebral Artery Occlusion (MCAO), the GRb1 group received intranasal GRb1 (1.25 mg/kg or 12.5 mg/kg)
  • However, its bioavailability is low after oral administration due to poor absorption.
  • Ginsenoside Rb1 was administrated intranasally at a dose of 12.5 mg/kg.
  • First, the concentration of GRb1 in brain tissues and plasma after intranasal and intravenous delivery was calculated using HPLC-MS/MS methods in male Sprague-Dawley rats (250±10 g). 
  • Intranasal GRb1 was considered brain-targeting if the value of the drug targeting index (DTI) was greater than 1. 
  • After intranasal administration, drugs can be directly transported from the nasal cavity to the CNS via the olfactory neuroepithelium and trigeminal nerve system. Besides, drugs may also be quickly absorbed into circulation due to the large absorption area and sufficient blood supply of nasal mucosa and then transported to the CNS
  • [Statistical Analysis]
    • The F-test was performed for the two group comparisons of the pharmacokinetic data. When the variance was equal, the data were compared using the independent t-test. When the variance was unequal, the data were compared by Welch’s test. 
    • Multiple group comparisons for the infarct volumes and protein levels were performed by one-way analysis of variance (ANOVA), followed by Tukey’s test. 


케타민은 24시간 이내에 신속한 항우울 효과를 보였다. 글루탐산 수용체는 NMDA, AMPA, 카이네이트 (kainate) 수용체로 분류되는데, 케타민은 NMDA 수용체를 비선택적으로 차단함으로 작용을 나타낸다. 케타민의 항우울 효과가 NMDA 수용체 차단에 의한 AMPA 수용체의 상대적 활성화와 관계 있을 것이라는 가설을 검증하기위하여 AMPA 수용체 차단제인 NBQX를 전처치하고 케타민의 효과를 강제수영 검사로 실험한 결과, NBQX 전처치는 삼환계 항우울제인 이미프라민(imipramine)의 항우울 작용에는 영향을 주지 않는 반면 케타민의 항우울 작용은 소실되었다.



:  진세노사이드 Rg3, Rb2, Rg1, Rd 또는 Rb1을 추가로 포함하며, 상기 추가되는 진세노사이드의 함량이 진세노사이드 Re의 함량보다 적은 것을 특징으로 하는 약학적 조성물

진세노사이드 Rb1(ginsenoside Rb1)을 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물

Intranasal Delivery of Microspheres Loaded with 20 (R)-ginsenoside Rg3 Enhances Anti-Fatigue Effect in Mice

Ginsenoside Rb1 rescues anxiety-like responses in a rat model of post-traumatic stress disorder

Korean Red Ginseng prevents posttraumatic stress disorder–triggered depression-like behaviors in rats via activation of the serotonergic system

Ginsenosides: A Potential Neuroprotective Agent

Gintonin attenuates depressive-like behaviors associated with alcohol withdrawal in mice

The effect of ginsenosides on depression in preclinical studies: A systematic review and meta-analysis



라벨:

댓글

댓글 쓰기

이 블로그의 인기 게시물

oral vs intranasal

Fast onset of action and the analgesic and sedative efficacy of essential oil from Rhizoma Chuanxiong after nasal administration. Pharmazie. 2010 Chuanxiong had faster onset of action as well as better analgesic and sedative efficacy after i.n. administration than given orally. Oil was collected from the condenser, dried over anhydrous sodium sulfate, and the recorded yield of the sample was 0.25% Sedative and anticonvulsant activities of styrax after oral and intranasal administration in mice. Pharm Biol. 2011 styrax had faster onset of action (5 vs. 30 min) and better anticonvulsant efficacy (25, 50 vs. 100, 200 mg/kg) by intranasal route in comparison with that by intragastric route. vehicle (3% Tween 80)  Locomotor activity  Locomotor activity was determined in each mouse after extract administration.  Prior to assay, mice were placed into a locomotor monitoring cage and allowed to habituate to the cage for 5min (0–5min after the administration).  Each mouse was ...
댓글 쓰기
자세한 내용 보기